Table 1.
Demographic and clinical characteristics of all patients at baseline
| Patient, n | Sex | Age | BCVA Snellen /LogMAR | CMT (µm) | SFCTa (µm) | Sub-PPE choroidal thicknessb (µm) | PPE widthc (µm) | PPE heightd (µm) | Follow-up time (months) | Time to PCV (months) | Disruption of EZ | CVH | Co-existing medical conditions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 64 | 0.80/0.10 | 223 | 230 | 309 | 382 | 42 | 153 | 81 | No | No | HTN |
| 2 | F | 59 | 1.00/0.00 | 213 | 372 | 270 | 1560 | 44 | 62 | 48 | No | Yes | OA |
| 3 | M | 74 | 0.40/0.40 | 207 | 380 | 251 | 888 | 36 | 83 | 37 | No | Yes | DM |
| 4 | F | 55 | 1.00/0.00 | 232 | 478 | 507 | 362 | 65 | 31 | 18 | Yes | Yes | DM, HTN |
| 5 | F | 51 | 0.63/0.20 | 223 | 446 | 307 | 1763 | 43 | 86 | 84 | Yes | Yes | HTN |
| 6 | M | 64 | 1.00/0.00 | 222 | 237 | 358 | 1950 | 87 | 77 | 48 | Yes | No | None |
| 7 | M | 72 | 0.63/0.20 | 203 | 341 | 324 | 2380 | 94 | 33 | 31 | No | Yes | None |
BCVA Best corrected visual acuity, LogMAR Logarithm of the minimum angle of resolution, CMT Central macular thickness, SFCT Subfoveal choroidal thickness, PPE Pachychoroid pigment epitheliopathy, PED Pigment epithelium detachment, PCV Polypoidal choroidal vasculopathy, EZ Ellipsoid zone, CVH choroidal vascular hyperpermeability, HTN Hypertension, OA Osteoarthritis, DM Diabetes mellitus
aChoroidal thickness was measured from the outer portion of the hyperreflective line indicating RPE to the inner surface of sclera on OCT. SFCT was measured at the center of the macula
bSub-PPE choroidal thickness was measured at the center of the PPE lesion on OCT
cPPE width was measured from the outer portions of the widest points of the PPE lesions on OCT. If there was no normal appearing RPE between closely located PPE lesions, these lesions were counted as a single lesion
dPPE height was measured from the highest point of PPE lesions to Bruch’s membrane